Last reviewed · How we verify
NCT06752746
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
Phase 1 trial testing 9MW3011 in Polycythemia Vera in 108 participants. Currently enrolling.
31 August 2025
Quick facts
| Lead sponsor | Mabwell (Shanghai) Bioscience Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 108 |
| Start date | 21 March 2024 |
| Primary completion | 31 August 2025 |
| Estimated completion | 30 June 2026 |
| Sites | 6 locations across China |
Drugs / interventions tested
- 9MW3011 — full drug profile →
Conditions studied
- Polycythemia Vera — all drugs for Polycythemia Vera →
Sponsor
Mabwell (Shanghai) Bioscience Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with Polycythemia Vera. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of 9MW3011 in Chinese patients with Polycythemia Vera（PV）.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Modern and multidisciplinary care in polycythemia vera.
Palandri F, Sartor C, Pileri A, Addimanda O, et al · · 2026 · PMID 41999414 · DOI 10.1007/s00277-026-06970-w
Verify or expand the search:
- PubMed search for NCT06752746
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 9MW3011
Trials testing the same drug.
- NCT06389942 — Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject · Phase 1 · completed
Other recruiting trials for Polycythemia Vera
Currently open trials in the same condition.
- NCT07203768 — A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes · recruiting
- NCT07362225 — MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel · recruiting
- NCT06661915 — A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) · Phase 2 · recruiting
- NCT06752941 — LOW-PV Continuation · recruiting
- NCT06734637 — Efficacy and Safety of Peginterferon in ET and PV. · NA · recruiting
Other Mabwell (Shanghai) Bioscience Co., Ltd. trials
Trials by the same sponsor.
- NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07314723 — 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer · Phase 2 · recruiting
- NCT06926998 — 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors · Phase 1, PHASE2 · not yet recruiting
- NCT06804590 — A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis · Phase 3 · recruiting
- NCT06692166 — A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Ca · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06752746 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mabwell (Shanghai) Bioscience Co., Ltd.
- Last refreshed: 11 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06752746.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing